EMA Authorised: Rxulti (brexpiprazole) — Otsuka Pharmaceutical Netherlands B.V.

View source ↗

Summary

The European Medicines Agency authorised Rxulti (brexpiprazole) for schizophrenia in the European Union. The marketing authorisation holder is Otsuka Pharmaceut…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• RXULTI (brexpiprazole)

Snippet

Status: Authorised. Therapeutic area: Schizophrenia. MAH: Otsuka Pharmaceutical Netherlands B.V.. Decision date: 15/01/2025